<p>ImmuCell（納斯達克代碼：ICCC - 獲取免費報告）於週四發佈了季度財報。這家生物技術公司報告的每股收益（EPS）為（$0.02），據 Zacks 報道。ImmuCell 的股本回報率為 6.25%，淨利潤率為 6.23%。</p>
<h2>ImmuCell 價格表現</h2>
<p>週四交易中，ICCC 股價下跌$0.08，達到$6.05。該公司的交易量為 6,393 股，而其平均交易量為 18,710 股。該公司的市值為 5473 萬美元，市盈率為 31.84，貝塔值為 0.29。該公司 50 日簡單移動平均線為$6.21，200 日簡單移動平均線為$6.23。ImmuCell 的 1 年最低價為$3.38，1 年最高價為$7.60。該公司的速動比率為 1.99，流動比率為 3.85，債務股本比率為 0.28。</p>
<h2>華爾街分析師觀點</h2>
<p>另外，Weiss Ratings 在 11 月 7 日的研究報告中將 ImmuCell 的評級從 “持有（c-）” 下調至 “賣出（d+）”。根據 MarketBeat.com 的數據，一位股票研究分析師對該股票給予了賣出評級，目前 ImmuCell 的共識評級為 “賣出”。</p>
<p><strong>獲取我們關於 ImmuCell 的最新股票報告</strong></p>
<h2>對 ImmuCell 的對沖基金觀點</h2>
<p>一家機構投資者最近增加了對 ImmuCell 股票的持倉。根據該公司在最近向證券交易委員會提交的文件，Geode Capital Management LLC 在第二季度將其在 ImmuCell Corporation（納斯達克代碼：ICCC - 免費報告）的持股比例提高了 4.2%。該機構投資者在本季度額外購買了 2,907 股後，持有 71,852 股這家生物技術公司的股票。Geode Capital Management LLC 在最近一個季度末持有的 ImmuCell 股票價值約為 50 萬美元，佔 ImmuCell 的約 0.79%。13.47% 的股票由機構投資者持有。</p>
<h2>關於 ImmuCell</h2>
<p>（獲取免費報告）</p>
<p>ImmuCell Corporation 是一家動物健康公司，開發、製造和銷售增強美國及國際乳牛和肉牛健康與生產力的產品。該公司通過兩個部門運營，分別是腹瀉和乳腺炎。它提供 First Defense，一種針對小牛的口服腹瀉預防產品，聲稱對 E 有防護作用。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，而不是 ImmuCell</li>
<li>什麼是 MACD 指標，如何在交易中使用它</li>
<li>dLocal 儘管第三季度業績出色，但仍下跌——投資者錯過了什麼</li>
<li>資產配置：成功投資組合的關鍵。你在關注自己的投資組合嗎？</li>
<li>Ondas Holdings 在無人機需求激增中發出反彈信號</li>
<li>技術指標如何幫助你找到被低估的股票</li>
<li>在艾格的魔法觸碰下，迪士尼 2026 年的前景變得更加光明</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUNDQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUNDQw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 ImmuCell 嗎？</h2>
<p>在你考慮 ImmuCell 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 ImmuCell 並不在名單上。</p>
<p>雖然 ImmuCell 目前在分析師中被評為賣出，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

ICCC

<p>ImmuCell（納斯達克代碼：ICCC）報告季度每股虧損 0.02 美元，股本回報率為 6.25%，淨利潤率為 6.23%。股價下跌 0.08 美元，至 6.05 美元。Weiss Ratings 將該股票評級下調至 “賣出”。Geode Capital Management 在第二季度增持了該公司的股份，增幅為 4.2%。ImmuCell 專注於乳牛和肉牛的動物健康產品</p>

<p>ImmuCell (NASDAQ:ICCC - Get Free Report) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, Zacks reports. ImmuCell had a return on equity of 6.25% and a net margin of 6.23%.</p>
<div class="lb-trans"><p>ImmuCell（納斯達克代碼：ICCC - 獲取免費報告）於週四發佈了季度財報。這家生物技術公司報告的每股收益（EPS）為（$0.02），據 Zacks 報道。ImmuCell 的股本回報率為 6.25%，淨利潤率為 6.23%。</p>
</div><h2>ImmuCell Price Performance</h2>
<div class="lb-trans"><h2>ImmuCell 價格表現</h2>
</div><p>ICCC traded down $0.08 during trading on Thursday, reaching $6.05. The company's stock had a trading volume of 6,393 shares, compared to its average volume of 18,710. The company has a market cap of $54.73 million, a price-to-earnings ratio of 31.84 and a beta of 0.29. The firm has a fifty day simple moving average of $6.21 and a two-hundred day simple moving average of $6.23. ImmuCell has a 1 year low of $3.38 and a 1 year high of $7.60. The company has a quick ratio of 1.99, a current ratio of 3.85 and a debt-to-equity ratio of 0.28.</p>
<div class="lb-trans"><p>週四交易中，ICCC 股價下跌$0.08，達到$6.05。該公司的交易量為 6,393 股，而其平均交易量為 18,710 股。該公司的市值為 5473 萬美元，市盈率為 31.84，貝塔值為 0.29。該公司 50 日簡單移動平均線為$6.21，200 日簡單移動平均線為$6.23。ImmuCell 的 1 年最低價為$3.38，1 年最高價為$7.60。該公司的速動比率為 1.99，流動比率為 3.85，債務股本比率為 0.28。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Separately, Weiss Ratings lowered ImmuCell from a &#34;hold (c-)&#34; rating to a &#34;sell (d+)&#34; rating in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, ImmuCell currently has a consensus rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 11 月 7 日的研究報告中將 ImmuCell 的評級從 “持有（c-）” 下調至 “賣出（d+）”。根據 MarketBeat.com 的數據，一位股票研究分析師對該股票給予了賣出評級，目前 ImmuCell 的共識評級為 “賣出”。</p>
</div><p><strong>Get Our Latest Stock Report on ImmuCell</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 ImmuCell 的最新股票報告</strong></p>
</div><h2>Hedge Funds Weigh In On ImmuCell</h2>
<div class="lb-trans"><h2>對 ImmuCell 的對沖基金觀點</h2>
</div><p>An institutional investor recently raised its position in ImmuCell stock. Geode Capital Management LLC raised its stake in ImmuCell Corporation (NASDAQ:ICCC - Free Report) by 4.2% in the 2nd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor owned 71,852 shares of the biotechnology company's stock after buying an additional 2,907 shares during the quarter. Geode Capital Management LLC owned approximately 0.79% of ImmuCell worth $500,000 at the end of the most recent quarter. 13.47% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一家機構投資者最近增加了對 ImmuCell 股票的持倉。根據該公司在最近向證券交易委員會提交的文件，Geode Capital Management LLC 在第二季度將其在 ImmuCell Corporation（納斯達克代碼：ICCC - 免費報告）的持股比例提高了 4.2%。該機構投資者在本季度額外購買了 2,907 股後，持有 71,852 股這家生物技術公司的股票。Geode Capital Management LLC 在最近一個季度末持有的 ImmuCell 股票價值約為 50 萬美元，佔 ImmuCell 的約 0.79%。13.47% 的股票由機構投資者持有。</p>
</div><h2>About ImmuCell</h2>
<div class="lb-trans"><h2>關於 ImmuCell</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.</p>
<div class="lb-trans"><p>ImmuCell Corporation 是一家動物健康公司，開發、製造和銷售增強美國及國際乳牛和肉牛健康與生產力的產品。該公司通過兩個部門運營，分別是腹瀉和乳腺炎。它提供 First Defense，一種針對小牛的口服腹瀉預防產品，聲稱對 E 有防護作用。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than ImmuCell</li>
<li>What is the MACD Indicator and How to Use it in Your Trading</li>
<li>dLocal Falls Despite Blowout Q3 Results—What Investors Are Missing</li>
<li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li>
<li>Ondas Holdings Signals a Rebound as Drone Demand Soars</li>
<li>How Technical Indicators Can Help You Find Oversold Stocks</li>
<li>Disney’s 2026 Outlook Brightens Under Iger's Magic Touch</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，而不是 ImmuCell</li>
<li>什麼是 MACD 指標，如何在交易中使用它</li>
<li>dLocal 儘管第三季度業績出色，但仍下跌——投資者錯過了什麼</li>
<li>資產配置：成功投資組合的關鍵。你在關注自己的投資組合嗎？</li>
<li>Ondas Holdings 在無人機需求激增中發出反彈信號</li>
<li>技術指標如何幫助你找到被低估的股票</li>
<li>在艾格的魔法觸碰下，迪士尼 2026 年的前景變得更加光明</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUNDQw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=ICCC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ImmuCell Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 ImmuCell 嗎？</h2>
</div><p>Before you consider ImmuCell, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 ImmuCell 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 ImmuCell 並不在名單上。</p>
</div><p>While ImmuCell currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 ImmuCell 目前在分析師中被評為賣出，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

ImmuCell（NASDAQ: ICCC）宣佈季度財報結果